Genmab A/S
GMAB21.975USD
+0.195+0.90%
交易中 （美东）报价延迟15分钟
1.39B总市值
0.41市盈率 TTM
关于 Genmab A/S 公司
Genmab A/S 是一家总部位于丹麦的国际生物技术公司。该公司专门从事用于治疗癌症的抗体疗法的研发。该公司是以下获批抗体的创造者：用于治疗某些多发性骨髓瘤适应症的 DARZALEX（daratumumab）、用于治疗复发型多发性硬化症成人患者的 Kesimpta、用于治疗甲状腺眼病的 TEPEZZA（teprotumumab）和用于治疗某些多发性骨髓瘤适应症成人患者的 FASPRO。Genmab 创造的首个获批疗法 Arzerra 获批用于治疗某些慢性淋巴细胞白血病适应症，在日本有售，也可通过同情用药或肿瘤学获取计划在其他地区有售。Genmab 开发了广泛的临床和临床前产品线，拥有四种抗体技术，即 DuoBody 双特异性平台、HexaBody 平台、DuoHexaBody 平台和 HexElect 平台。
公司简介
公司代码GMAB
公司名称Genmab A/S
上市日期Oct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
员工数量2682
证券类型Ordinary Share
年结日Oct 01
公司地址Carl Jacobsens Vej 30
城市VALBY
上市交易所OMX Nordic Exchange Copenhagen A/S
国家Denmark
邮编2500
电话4570202728
网址https://www.genmab.com/
公司代码GMAB
上市日期Oct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
暂无数据
业务
地区
业务USD
名称
营收
占比
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
持股股东
持股股东
占比
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
4.27%
Investment Advisor
2.99%
Hedge Fund
2.45%
Research Firm
0.51%
Pension Fund
0.03%
Bank and Trust
0.02%
Venture Capital
0.01%
Other
89.73%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
498
64.99M
10.26%
-6.57M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
2023Q1
481
44.22M
6.78%
-6.32M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
AllianceBernstein L.P.
14.73M
2.32%
-210.07K
-1.41%
Mar 31, 2025
Orbis Investment Management Ltd.
5.71M
0.9%
+2.90M
+102.83%
Mar 31, 2025
Citadel Advisors LLC
4.43M
0.7%
+1.33M
+43.16%
Mar 31, 2025
Two Sigma Investments, LP
3.87M
0.61%
+513.60K
+15.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.95M
0.47%
-433.32K
-12.82%
Mar 31, 2025
Harding Loevner LP
2.88M
0.45%
+637.43K
+28.41%
Mar 31, 2025
Renaissance Technologies LLC
2.26M
0.36%
+336.20K
+17.45%
Mar 31, 2025
Marshall Wace LLP
2.18M
0.34%
+1.06M
+94.38%
Mar 31, 2025
Brandywine Global Investment Management, LLC
1.72M
0.27%
+97.63K
+6.03%
Mar 31, 2025
First Trust Advisors L.P.
1.71M
0.27%
+65.52K
+3.98%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Tema Oncology ETF
3.66%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
WisdomTree BioRevolution Fund
0.99%
iShares Biotechnology ETF
0.87%
First Trust NASDAQ BuyWrite Income ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
Avantis International Equity ETF
0.07%
ActivePassive International Equity ETF
0.07%
Avantis International Large Cap Value ETF
0.05%
查看更多
Tema Oncology ETF
占比3.66%
First Trust NYSE Arca Biotechnology Index Fund
占比3.45%
WisdomTree BioRevolution Fund
占比0.99%
iShares Biotechnology ETF
占比0.87%
First Trust NASDAQ BuyWrite Income ETF
占比0.2%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
Invesco Nasdaq Biotechnology ETF
占比0.1%
Avantis International Equity ETF
占比0.07%
ActivePassive International Equity ETF
占比0.07%
Avantis International Large Cap Value ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
